Tower Research Capital (TRC)’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-13
Closed -$1K – 6732
2021
Q3
$1K Buy
+13
New +$924 ﹤0.01% 5578

Other funds holding FRLN

Tower Research Capital (TRC)'s FRLN Position: Q4 2021 in Review

Tower Research Capital (TRC) sold out of Freeline Therapeutics Holdings (FRLN) in Q4 2021, closing a stake of 13 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in FRLN in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 18 funds tracked by Wall St. Rank hold FRLN as of Q4 2021.

  • Tower Research Capital (TRC) reported no remaining Freeline Therapeutics Holdings position as of Q4 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 13 Freeline Therapeutics Holdings shares in Q4 2021, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Freeline Therapeutics Holdings in Q3 2021 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Freeline Therapeutics Holdings position peaked at $1K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q4 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.